Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in
combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with
advanced hematologic malignancies